

# List of attendees for Orphan Drugs and Rare Diseases annual conference has been published

*SMi Group Reports: There is now 5 weeks left before the Orphan Drugs and Rare Diseases Conference. We've got the list of participants that was released today.*

LONDON, UNITED KINGDOM, September 16, 2015  
/EINPresswire.com/ -- SMi's 4th annual [Orphan Drugs](#) and Rare Diseases Conference will be taking place in London, UK, on 19th – 20th October 2015.

SMi Group Reports (15.09.15. – London, UK): There is now 5 weeks left before the Conference.

We've got the [list](#) of participants that was released today. To review, please visit: [www.orphandrugs-event.com](http://www.orphandrugs-event.com)



This must attend event will review recent developments in the orphan drug and rare diseases industry and provide attendees with the opportunity to gain in-depth knowledge by: Learning about key strategies and collaborations to accelerate rare disease clinical drug development, enhancing knowledge on the role of patient organisations in promoting drug development for their disease and discover how gene therapy is a very real factor in clinical trials.

“

5 weeks left before the Orphan Drugs and Rare Diseases Conference. Attendee list has been published today.

*SMi Group Ltd*

Why you should attend?

- Review how big pharma is positioning itself in the emerging orphan drug industry
- Discuss academic and big pharma perspectives on how to overcome the challenges of rare diseases
- Understand how patients and families are key team players in improving therapy development

Key speakers in 2015 include: Rare Disease UK (RDUK), GSK Rare Diseases, GSK, Roche Pharma Research and Early Development, International Regulatory Affairs department- GENETHON, Rare Disease Research Unit –Pfizer, DORPHAN S.A., Abeona Therapeutics, and many more

To register today please visit: [www.orphandrugs-event.com](http://www.orphandrugs-event.com)

Alternatively, contact Fateja Begum: +44 (0) 20 7827 6184/ [fbegum@smi-online.co.uk](mailto:fbegum@smi-online.co.uk)

In addition to the event, there will be two interactive post-conference [workshops](#):

Market Access to Orphan Drugs: Controversies, Trends and Solutions, led by Colette Hamilton, Managing Director, ATP Market Access.

And The Rare Disease Patient Perspective - From Regulatory to Clinical Execution, led by Christa van Kan, Team Lead Clinical Execution, PSR Orphan Experts.

For more information please visit: [www.orphandrugs-event.com](http://www.orphandrugs-event.com)

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Anna Serazetdinova  
SMi Group Ltd  
+44 (0) 20 7827 6184  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.